VBWG

86 related results for Core Curriculum


What Have We Learned From Recent Trials for PAD and Where Are We Headed?

William R. Hiatt, MD
University of Colorado School of Medicine
Denver, CO 

Recent Advances in Diagnostic Imaging for Peripheral Arterial Disease

Joao A. C. Lima, MD, FACC
Johns Hopkins School of Medicine
Baltimore, MD

Nanotherapeutic Solutions for Peripheral Arterial Disease

John P. Cooke, MD, PhD, FACC
Houston Methodist Research Institute
Houston, TX

HIV, Inflammation and Cardiovascular Disease

Priscilla Y. Hsue, MD, FACC
UCSF School of Medicine
San Francisco, CA

Transcatheter Mitral Valve Replacement: Hope or Hype?

Howard C. Herrmann, MD, FACC
University of Pennsylvania
Philadelphia, PA

Utilizing Novel Therapies in Atherosclerosis: From Antibodies to Nanotechnology

Erik Stroes MD, PhD
Academic Medical Center
Amsterdam, Netherlands

Modifying CVD Risk by Managing Hyperglycemia: The Dawn of a New Era?

Jorge Plutzky, MD
Brigham and Women's Hospital
Boston, MA

Advancing the Cardiovascular Care of Our Cancer Patients: Where Are We Now?

Javid Moslehi, MD
Vanderbilt University
School of Medicine
Nashville, TN

Tailoring Oral Anticoagulation in Elderly Patients with Atrial Fibrilation

Christopher Granger, MD
Duke University
School of Medicine
Durham, NC

How We Should Manage HTN in Adults: The Importance of Diastolic Blood Pressure with Lower Systolic Targets

Deepak Bhatt, MD, MPH
Brigham and Women's Hospital 
Heart and Vascular Center
Boston, MA

Living with Heart Disease in Old Age: Shifting Priorites of Care for Older Cardiac Patients

Daniel Forman, MD
Professor, Department of Medicine
University of Pittsburgh

HFpEF in Older Adults: TTR Amyloid, Under Diagnosed and Treatable?

Mathew Maurer, MD
Columbia University
Medical Center
New York, NY

CKD: An Independent CV Risk Factor in the Elderly

George Bakris, MD
University of Chicago Medicine
Chicago, IL

No Automatic Prescribing in Those > 75 Years. Why Guideline Directed Clinician-Patient-Risk Discussion Crucial

Neil Stone, MD
Northwestern University
Feinburg School of Medicine
Chicago, IL

The Emerging Role of Gut Microbiota in CVD and Thrombosis.

Stanley L. Hazen, MD, PhD
Cleveland Clinic
Cleveland, OH

Reducing CV Risk with Glucose Lowering Drugs: Recent Breakthroughs.

Silvio E. Inzucchi, MD
Yale University School of Medicine
New Haven, CT

Eliminating Barriers That Prevent Optimal Stroke Prevention in Patients with Afib.

Christian T. Ruff, MD
Brigham and Women’s Hospital
Boston, MA

The Next Frontier in Heart Failure: Where Are We Going?

Scott D. Solomon, MD
Brigham and Women’s Hospital
Boston, MA 

Cardiorenal Disorders: Recent Advances, Novel Therapies.

Peter A. McCullough, MD, MPH
Baylor Heart and Vascular Institute
Dallas, TX

New Oral Interventions for Heart Failure.

Javed Butler,  MD, MPH
Stony Brooke University School of Medicine
Stony Brook, NY

PCSK9 and Atherosclerosis: Will We Target Risk with Monoclonal Antibodies or Only LDL-C?

Michael J. Koren, MD
Jacksonville Ctr. For Clinical Research

HDL Dysfunction in Coronary Artery Disease: An Enigma or Dead?

Stephen J. Nicholls, MBBS, PhD
South Australian Health and Medical Research Institute

Emerging Therapies on the Horizon for Hypertriglyceridemia

Ira Goldberg, MD
NYU Langone Medical Center

Turning White Fat to Brown: Foe to Friend or Not?

Jorge Plutzky MD, Brigham and Women's Hospital

High LP(a): Causal Role in Calcific Stenosis and Other CV Diseases

Sotirios Tsimikas MD, UC San Diego School of Medicine

Direct Inhibition of Inflammation: CANTOS, CIRT, and Beyond

Paul M Ridker MD, Brigham and Women's Hospital

New Approaches to Modifying Risk by Improved Glycemic Management

Deepak L Bhatt MD, MPH, Harvard Medical School

Core Curriculum

Progress and Promise in RAAS Blockade

View/Download individual slides (82 Slides)

Core Curriculum

Leading the Way in Cardiovascular Regenerative Medicine

View/Download individual slides (54 Slides)

Core Curriculum

Vascular Dysfunction: Sequelae of Acute Hypertension

View/Download individual slides (84 Slides)

Core Curriculum

Hyperglycemia and Acute Coronary Syndromes

View/Download individual slides (84 Slides)

Core Curriculum

Contemporary Management of Cardiometabolic Risk

View/Download individual slides (105 Slides)

Core Curriculum

Advancing Our Understanding of RAAS Modulation in High-Risk Patients

View/Download individual slides (67 Slides)

Core Curriculum

Targeting Insulin Resistance for Vascular Protection

View/Download individual slides (120 Slides)

Core Curriculum

Contemporary Management of Myocardial Ischemia

View/Download individual slides (119 Slides)

ExTRACT-TIMI 25 study

Results from ExTRACT-TIMI 25: The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25

Core Curriculum

Antiplatelet Interventions in ACS

View/Download individual slides (104 Slides)

Core Curriculum

New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks

View/Download individual slides (129 Slides)

Vascular Biology in Clinical Practice © Vol. 7, No. 1

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Core Curriculum

Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology

View/Download individual slides (94 Slides)

Core Curriculum

The Renin-Angiotensin-Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction

View/Download individual slides (93 Slides)

Core Curriculum

RAAS Modulation: Novel Strategies for Reducing Cardiovascular Risk

View/Download individual slides (82 Slides)

Core Curriculum

Improving Outcomes in Heart Failure: New Insights From Vascular Biology

View/Download individual slides (53 Slides)

TNT: New data on intensive lipid lowering in stable CAD patients

View/Download individual slides (16 Slides)

New data on optimal BP lowering in CAD patients: CAMELOT

The results of the Comparison of Amlodipine vs Enalapril to Limit Occurrence of Thrombosis (CAMELOT) study have recently been published.

Vascular Biology in Clinical Practice © Vol. 6, No. 3

A HOPE FOR PEACE? Update on the role of ACE inhibition in CAD patients

This monograph, A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV - Update: RAAS manipulation and cardiovascular risk--Hope for Peace?

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section V: Multiple risk and CV disease prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV: RAAS manipulation and cardiovascular risk

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section III: Heart failure: The new vascular biology imperative to blunt progression

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section II: Blunting the atherosclerotic process: The case for aggressive lipid management

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section I: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section V: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in the failing heart

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section I: RAAS manipulation

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

RITA 3: Benefit of early invasive strategy in moderate-risk unstable angina patients

Final results of RITA 3 (Randomized Intervention Trial of unstable Angina) confirm that an interventional strategy results in a statistically significant reduction in the combined outcome of death, nonfatal myocardial infarction (MI), or refractory angina.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in heart failure

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section I: RAS manipulation

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Curriculum Update # 7

Managing renal disease for risk reduction: The expanding role of ACE inhibition

Chronic renal disease is a problem of increasing magnitude in the United States.

Curriculum Update # 6

Managing lipids for risk reduction: Focus on the new National Cholesterol Education Program guidelines

This Curriculum Update presents new perspectives on cholesterol management as suggested by the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III).

MIRACL: Very early statin therapy not guided by cholesterol levels is beneficial in acute coronary syndromes

Final results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial have been published and confirm that treatment with atorvastatin 80 mg/d early during an acute coronary syndrome (ACS) reduces the risk of early recurrent events, primarily recurrent symptomatic ischemia during hospitalization.

Core Curriculum

Vascular biology for clinical practice: From basic concepts to mainstream medicine

Physicians who participated at recent Vascular Biology Working Group meetings have provided the direction for the development of these materials.

Curriculum Update #5

Interactions of lipids and RAS: Mechanisms for risk reduction

Hypertension and hypercholesterolemia, the major risk factors for atherosclerotic disease, are frequently associated.

Curriculum Update #4

Bradykinin and angiotensin-(1-7): Emerging allies in vascular function

The role of endothelial function in cardiovascular health provides an important conceptual framework for development of risk reduction strategies.

Core Curriculum

The endothelium: New insights into the origins and treatment of CAD

Participants at recent Vascular Biology Working Group meetings have reviewed and provided significant direction in the development of this slide/lecture program entitled The endothelium: New insights into the origins and treatment of CAD.

Postintervention Continuum of Care Update: Ultrasound Assessment of Plaque Dynamics

Lipids and plaque on ultrasound: New views and new dimensions

This slide lecture material is an update to the core curriculum entitled Postintervention Continuum of Care: Focus on Lipids

Curriculum Update #3

Clinical Trials Update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

This Curriculum Update highlights important recent trials of tissue ACE inhibition in patients with cardiovascular disease and preserved left ventricular function.

Curriculum Update #2

From hypertension to LVH and heart failure

This new program focuses on an area in which our understanding of vascular biology may have had the most profound impact on clinical practice to date.

Vascular Biology in Clinical Practice

The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome

This discourse is based on the proceedings of a national faculty meeting of the Vascular Biology Working Group held in Orlando earlier this year that explored the clustering of metabolic abnormalities associated with what previously has been recognized by many as "syndrome X.

Vascular Biology in Clinical Practice © Vol. 1, No. 3

From hypertension to LVH and heart failure

Participants at recent Vascular Biology Working Group meetings have reviewed and provided significant direction in the development of this slide/lecture program entitled The endothelium: New insights into the origins and treatment of CAD.

The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome

The attached slide materials represent the seventh in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.

Curriculum Update #1

Overview of clinical trials to improve endothelial function

The contents of the curriculum update represent a concise overview of clinical trials in the emerging field of study relating to the endothelium and its role in cardiovascular health and disease.

New data on the anti-ischemic effects of ACE inhibition

During the past decade, results from a number of clinical trials have revolutionized the way clinicians treat CHD and CAD.

Core Curriculum

Endothelial function: Changing the pattern of treating CV disease

The attached slide materials represent the fifth in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.

Focus: Lipids and the Endothelium

The Endothelium: Impact on CAD treatment strategies

These slide materials represent the third in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.